Agenda for October 2026 Cancer Treatments (CTAC) meeting

Applications

Tislelizumab (branded as TEVIMBRA) for gastric or gastro-oesophageal junction cancer

The Committee will discuss an application for tislelizumab for the treatment of people living with advanced or metastatic gastric or gastro-oesophageal junction cancer. The application is for first line treatment for people whose cancer is advanced or has spread, and the tumour is HER2-negative, and has a PD-L1 score of 5% or higher.

Application for tislelizumab(external link)

Tislelizumab (branded as TEVIMBRA) for oesophageal squamous cell cancer

The Committee will discuss tislelizumab for the treatment of people living with advanced or metastatic oesophageal squamous cell cancer. The application is for first line treatment for people whose cancer is advanced or has spread and whose tumour has a PD-L1 score of 1% or higher.

Application for tislelizumab(external link)

Pembrolizumab (branded as Keytruda) for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancers

The Committee will discuss an application for pembrolizumab for people living with unresectable or metastatic cancers, with specific genetic features (known as MSI-H or dMMR), whose cancer has progressed despite previous treatment.

Application for pembrolizumab(external link)

Advisory meeting agenda setting

The scheduling and agenda setting process for advisory meetings considers multiple factors. We aim to balance the relative priorities of clinical advice needed across indications, the factors for consideration for each application (for example unmet health need), the time since applications were received and the internal and advisor resource available to support each meeting.